What are the recommended dosing, monitoring parameters, and contraindications for vadadustat in adult patients with anemia due to chronic kidney disease, both dialysis‑dependent and non‑dialysis‑dependent?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Vadadustat for Anemia in Chronic Kidney Disease

Primary Recommendation

Vadadustat is FDA-approved ONLY for dialysis-dependent CKD patients who have been on dialysis for at least 3 months; it should NOT be used in non-dialysis CKD patients due to increased risks of mortality, stroke, myocardial infarction, and serious organ injury. 1


Approved Indication

Vadadustat (VAFSEO) is indicated exclusively for treating anemia in adults with dialysis-dependent chronic kidney disease (DD-CKD) 1. The 2026 KDIGO guidelines position HIF-PHIs like vadadustat as alternatives when patients prefer oral agents, cannot tolerate ESAs, or lack access to refrigeration 2.


Dosing Regimen

Starting Dose

  • 300 mg once daily regardless of prior ESA use 3, 1

Dose Adjustments

  • Titrate in 150 mg increments (150,300,450, or 600 mg daily) based on hemoglobin response 3, 1
  • Maximum dose: 600 mg once daily 1
  • Adjust every 4 weeks or longer to achieve target hemoglobin 1

Target Hemoglobin

  • 10-11 g/dL (U.S. target range) 3, 1
  • Do NOT target hemoglobin ≥11.5 g/dL per KDIGO guidance 2

Administration

  • Take with or without food 1
  • Can be administered 4 hours before or 2 hours after dialysis (no significant PK differences) 1

Monitoring Parameters

Before Initiation

  • Hemoglobin, ferritin, transferrin saturation (TSAT)
  • ALT, AST, and bilirubin (mandatory baseline) 1
  • Blood pressure
  • Iron parameters: Ensure ferritin ≤500 ng/mL and TSAT ≤30% per KDIGO 2

During Treatment

First 6 Months:

  • Monthly ALT, AST, and bilirubin 1
  • Hemoglobin every 2-4 weeks after initiation or dose adjustment 2, 1
  • Blood pressure at each visit 1

After 6 Months:

  • Liver enzymes as clinically indicated 1
  • Hemoglobin monitoring frequency per KDIGO applies as for ESAs 2
  • Iron parameters every 3 months 2

Discontinuation Criteria

  • Persistent ALT or AST >3× ULN 1
  • ALT/AST >3× ULN with bilirubin >2× ULN 1
  • Insufficient erythropoietic response after 3-4 months 2

Absolute Contraindications

  1. Uncontrolled hypertension 1
  2. Active malignancy 2, 1
  3. Recent cardiovascular or vascular thrombotic event 2
  4. Non-dialysis-dependent CKD (safety not established; increased mortality and MACE risk observed in trials) 1

Critical Safety Warnings

Cardiovascular Risk

In the INNO2VATE trials (dialysis patients), vadadustat was non-inferior to darbepoetin alfa for MACE 3. However, in non-dialysis CKD patients (PRO2TECT trials), vadadustat increased mortality, stroke, MI, and serious acute kidney injury compared to darbepoetin alfa 3, 1.

Hepatotoxicity

  • ALT/AST elevations >3× ULN occurred in 3.8% and 1.8% of patients 1
  • Monthly monitoring mandatory for first 6 months 1
  • Not recommended in cirrhosis or active liver disease 1

Hypertension

  • Worsening hypertension: 14% (9.4 per 100 person-years) 1
  • Hypertensive crisis and encephalopathy reported 1
  • Monitor BP periodically and adjust antihypertensives 1

Gastrointestinal Erosion

  • Gastric/esophageal erosions: 6.4% (4.0 per 100 person-years) 1
  • Serious GI bleeding requiring transfusion: 3.4% 1
  • Higher risk in patients with peptic ulcer history, tobacco/alcohol use, or concurrent NSAIDs 1

Seizures

  • Incidence: 1.6% (1.0 per 100 person-years) 1
  • Monitor for premonitory neurologic symptoms 1

When to Consider Vadadustat Over ESAs

Per KDIGO 2026 guidelines 2:

  1. Patient preference for oral agent (convenience, avoids injections)
  2. ESA intolerance (injection site reactions, allergic responses)
  3. No access to refrigeration (ESAs require cold storage)
  4. ESA hyporesponsiveness (trial of HIF-PHI can be considered)

Drug Interactions

Significant Interactions (from FDA label) 1:

  • Probenecid: Increases vadadustat AUC by 65% (OATP1B1/1B3 inhibition)
  • Rifampin: Decreases vadadustat AUC by 48% (UGT induction)
  • Vadadustat increases rosuvastatin exposure by 71% (BCRP/OATP1B1/1B3 inhibition)
  • Vadadustat increases metformin AUC by 52% (OCT2/MATE inhibition)

Clinical Implication: Dose adjustments may be needed for concomitant statins and metformin.


Iron Management

Suspend vadadustat during active infection per KDIGO 2. Maintain iron parameters:

  • Ferritin <700 ng/mL and TSAT <40% (dialysis patients) 2
  • Withhold iron if ferritin >700 ng/mL or TSAT ≥40% 2

Vadadustat improves iron utilization by reducing hepcidin 4, 5, potentially reducing IV iron requirements.


Special Populations

Renal Impairment

  • Vadadustat clearance decreases with declining renal function 1
  • Exposures in DD-CKD are approximately 2-fold higher than healthy adults 1
  • No dose adjustment specified; titrate to hemoglobin response 1

Hepatic Impairment

  • No dose adjustment for moderate impairment (Child-Pugh B) 1
  • Unknown safety in severe impairment (Child-Pugh C) 1
  • Not recommended in cirrhosis or active liver disease 1

Pregnancy/Lactation

  • No human data available 1
  • Animal studies showed no fertility impairment at 1.5× MRHD 1

Common Pitfalls to Avoid

  1. Do NOT use in non-dialysis CKD patients – this is the most critical error given increased mortality risk 1
  2. Do NOT skip monthly liver monitoring in first 6 months – hepatotoxicity can be serious 1
  3. Do NOT use with active malignancy – HIF activation may promote tumor growth 2, 1
  4. Do NOT target hemoglobin >11.5 g/dL – increases cardiovascular risk per KDIGO 2
  5. Do NOT continue if no response after 3-4 months – discontinue per KDIGO 2

Efficacy Data

In the INNO2VATE trials (3,923 dialysis patients), vadadustat was non-inferior to darbepoetin alfa 3:

  • Mean hemoglobin change at weeks 24-36: vadadustat 0.19-1.26 g/dL vs. darbepoetin 0.36-1.58 g/dL
  • Patients achieving target hemoglobin: 43.6-60.1% (vadadustat) vs. 50.2-60.7% (darbepoetin)
  • MACE hazard ratio: 0.96 (95% CI 0.83-1.11) – demonstrating cardiovascular non-inferiority 3

Related Questions

What is the appropriate dosing and monitoring for Vadadustat (brand name Vafseo) in an adult patient with dialysis‑dependent chronic kidney disease?
What is the recommended dosing, contraindications, and monitoring for desidustat in adults with anemia due to chronic kidney disease?
How are hypoxia‑inducible factor (HIF) inhibitors—belzutifan for clear‑cell renal cell carcinoma and roxadustat, daprodustat, or vadadustat for anemia of chronic kidney disease—dosed, monitored, and what are their contraindications?
In a patient with stage 5 chronic kidney disease on dialysis, is it appropriate to administer an erythropoiesis‑stimulating agent (ESA) and intravenous iron on the same day?
Why should daprodustat be avoided in a chronic kidney disease patient not on dialysis?
What is the appropriate dose and tapering schedule of deflazacort for an adult with undifferentiated connective‑tissue disease (UCTD) experiencing a relapse?
What antibiotics are safe for treating a urinary tract infection during the first trimester of pregnancy?
How should I manage a 66-year-old woman with rising serum creatinine?
In an adult with undifferentiated connective tissue disease experiencing a relapse, which glucocorticoid—deflazacort, methylprednisolone, or prednisolone—is preferable?
In a patient with type 2 diabetes who is currently on metformin and has discontinued empagliflozin due to recurrent urinary tract infections, is glimepiride (Amaryl) the only sulfonylurea option?
Can a probiotic be used in an otherwise healthy adult with concurrent norovirus and Salmonella infection?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.